Biotechnology-Derived Pharmaceuticals
Start with the big picture
The lesson begins with recombinant DNA technology and its role in producing human proteins such as insulin, erythropoietin, and growth hormone. It then surveys monoclonal antibody formats, antibody–drug conjugates, strategies that can extend plasma half-life, and glycoengineering. Further sections introduce biosimilarity and interchangeability, gene therapy vectors, mRNA therapeutics, oligonucleotide drugs, CAR T-cell therapy, and CRISPR/Cas genome editing. The manufacturing material covers host cell selection and newer production approaches, alongside topics including personalized cancer vaccines, extracellular vesicles, regulatory guidance, cold-chain logistics, and rare diseases. Together, these areas show the breadth of biotechnology-derived medicines and the distinct design and production considerations they involve.
What you'll learn
- Describe how recombinant DNA technology supports production of therapeutic human proteins.
- Distinguish major monoclonal antibody formats and explain the purpose of antibody–drug conjugates.
- Identify approaches used to alter biologic persistence and antibody activity.
- Summarize delivery and action concepts for gene, mRNA, and oligonucleotide therapies.
- Recognize key themes in cell therapy, genome editing, and biologic manufacturing.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
